Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
John Owen Brennan Insider Profile
4 Followers
John Owen Brennan, Director at ImmunityBio, holds 25.00K shares in ImmunityBio (Ticker: IBRX). Most recently, John Owen Brennan Bought $25,000 shares of ImmunityBio on Jun 05, 2023 for an estimated value of 70.70K.
John Owen Brennan has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of John Owen Brennan's holdings
Insider Roles
Director
Roles that John Owen Brennan holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by John Owen Brennan
John Owen Brennan's Trading History
List of latest transactions for each holding click on a transaction to see John Owen Brennan's performance on stock
You May Also Like
John Owen Brennan insider profile FAQ
What is the percentage of profitable transactions made by John Owen Brennan?
The percentage of profitable transactions made by John Owen Brennan is ―.
What is the average return per transaction made by John Owen Brennan?
The average return per transaction made by John Owen Brennan is ―.
What stocks does John Owen Brennan hold?
John Owen Brennan holds: IBRX stocks.
What was John Owen Brennan’s latest transaction?
John Owen Brennan latest transaction was an Informative Buy of $70.70K.
What was John Owen Brennan's most profitable transaction?
John Owen Brennan’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is John Owen Brennan's role in ImmunityBio?
John Owen Brennan's role in ImmunityBio is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.